Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, has initiated a study to evaluate shock wave therapy as a treatment for Exercised Induced Pulmonary Hemorrhage.
ANN ARBOR, MI / ACCESSWIRE / June 13, 2022 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering diagnostic and therapeutic products for companion animals, has initiated a study to evaluate shock wave therapy as a treatment for Exercised Induced Pulmonary Hemorrhage (EIPH).
EIPH or “bleeding” occurs in horses when pulmonary blood vessels in the lungs rupture after intense exercise. The study aims to understand the effect of shock wave therapy on horses with confirmed EIPH by evaluating bleeding episodes and performance in barrel racing horses, before and after shockwave therapy. This study, currently with eight horses enrolled, is being performed by Dr. Beau Whitaker at Brazos Valley Equine Hospital in Salado, Texas.
“Exercise induced pulmonary hemorrhage (EIPH) is one of the most common performance limiting issues in speed event horses,” says Dr. Whitaker. “Other than the administration of Furosemide prior to competition and the use of nasal strips, no treatment or preventatives have shown to be effective at decreasing EIPH. To compound the issue, Furosemide is now becoming increasingly illegal to use pre-race. Shock wave therapy has shown anecdotal promise in limited cases to date as an effective method to mitigate EIPH. An effective non pharmaceutical EIPH preventative treatment would be a game changer for the speed event disciplines that suffer from EIPH.”
Zomedica’s PulseVet® system is a world leader in electro-hydraulic shock wave technology for the treatment of a wide variety of conditions in veterinary patients. The high-energy sound waves stimulate cells and release healing growth factors in the body that reduce inflammation and accelerate bone and soft tissue development. PulseVet’s technology is used in conditions including tendon and ligament healing. bone healing, osteoarthritis, chronic pain, and wound healing.
“We are excited to pursue this potential and novel use for shock wave therapy,” said Trudy Gage, PulseVet’s Director of North American Sales and Client Education. “Whether it be rehabilitation from an injury or maintenance to stay at peak performance, Zomedica is committed to exploring means to provide the best possible care for horses at every level of training and competition.”
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
###
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://m.facebook.com/zomedica
- Twitter: https://twitter.com/zomedica
- Instagram: https://www.instagram.com/zomedica_inc
Reader Advisory
Except for statements of historical fact, this news release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, our ability to successfully integrate and operate the PulseVet business, the sufficiency of our budgeted capital and operating expenditures, the cost, adequacy and availability of supplies required for our operations, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results, and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate and operate the Pulse Vet business, uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty regarding the cost, adequacy and availability of supplies required for our operations; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations: risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
PCG Advisory Group
Kirin Smith, President
ksmith@pcgadvisory.com
+1.646.823.8656
SOURCE: Zomedica Corp.
View source version on accesswire.com:
https://www.accesswire.com/704823/Zomedica-to-Investigate-Shock-Wave-Therapy-of-Exercised-Induced-Pulmonary-Hemorrhage-in-Horses
